Brean Murray Maintains Sell on Idenix

Brean Murray Carret & Company has published a research report on Idenix Pharmaceuticals (NASDAQ: IDIX) showing that Gilead Sciences (NASDAQ: GILD) earnings call last night showed a decent profile that may be too good for IDX184 to be viable.

Brean Murray reiterates its Sell rating and $3 price target on Idenix, which closed yesterday at $13.19.